{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:49:50Z","timestamp":1794023390246,"version":"4.8.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bispecific antibodies (BsAbs) are a new group of targeted therapies that are revolutionizing the treatment landscape of B-cell non-Hodgkin\u2019s lymphoma (B-NHL). In the relapsed\/refractory setting, salvage chemotherapy and autologous stem cell transplantation are capable of curing 50% of patients, whereas the other half will have a dismal outcome with a median overall survival of less than 12 months. This unmet need reinforced the importance of innovative therapies like the BsAbs and CAR-T cell therapies. In this review, we delve into BsAbs in B-NHL from the preclinical development to clinical data in both refractory and frontline settings, and then discuss future perspectives.<\/jats:p>","DOI":"10.1038\/s41408-024-00989-w","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T01:01:55Z","timestamp":1706144515000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives"],"prefix":"10.1038","volume":"14","author":[{"given":"Iman","family":"Abou Dalle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5024-1713","authenticated-orcid":false,"given":"Remy","family":"Dulery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nour","family":"Moukalled","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Ricard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7316-5832","authenticated-orcid":false,"given":"Nicolas","family":"Stocker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2846-9428","authenticated-orcid":false,"given":"Jean","family":"El-Cheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7171-4997","authenticated-orcid":false,"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,25]]},"reference":[{"key":"989_CR1","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/ppo.0000000000000451","volume":"26","author":"L de Leval","year":"2020","unstructured":"de Leval L, Jaffe ES. Lymphoma Classification. Cancer J (Sudbury, Mass). 2020;26:176\u2013185. https:\/\/doi.org\/10.1097\/ppo.0000000000000451. e-pub ahead of print 2020\/06\/05","journal-title":"Cancer J (Sudbury, Mass)"},{"key":"989_CR2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235\u201342. https:\/\/doi.org\/10.1056\/NEJMoa011795. e-pub ahead of print 2002\/01\/25","journal-title":"N Engl J Med"},{"key":"989_CR3","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/jco.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184\u201390. https:\/\/doi.org\/10.1200\/jco.2010.28.1618. e-pub ahead of print 2010\/07\/28","journal-title":"J Clin Oncol"},{"key":"989_CR4","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1182\/bloodadvances.2019000102","volume":"3","author":"N Epperla","year":"2019","unstructured":"Epperla N, Badar T, Szabo A, Vaughn J, Borson S, Saini NY, et al. Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation. Blood Adv. 2019;3:1661\u20139. https:\/\/doi.org\/10.1182\/bloodadvances.2019000102. e-pub ahead of print 2019\/06\/07","journal-title":"Blood Adv"},{"key":"989_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N. Engl J Med. 2019;380:45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980. e-pub ahead of print 2018\/12\/07","journal-title":"N. Engl J Med"},{"key":"989_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/s1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20:31\u201342. https:\/\/doi.org\/10.1016\/s1470-2045(18)30864-7. e-pub ahead of print 2018\/12\/07","journal-title":"Lancet Oncol"},{"key":"989_CR7","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2021","unstructured":"Locke FL, Miklos DB, Jacobson CA, Perales M-A, Kersten M-J, Oluwole OO, et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N. Engl J Med. 2021;386:640\u201354. https:\/\/doi.org\/10.1056\/NEJMoa2116133","journal-title":"N. Engl J Med"},{"key":"989_CR8","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/s0140-6736(22)00662-6","volume":"399","author":"M Kamdar","year":"2022","unstructured":"Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet (Lond, Engl). 2022;399:2294\u2013308. https:\/\/doi.org\/10.1016\/s0140-6736(22)00662-6. e-pub ahead of print 2022\/06\/20","journal-title":"Lancet (Lond, Engl)"},{"key":"989_CR9","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130:1800\u20138. https:\/\/doi.org\/10.1182\/blood-2017-03-769620. e-pub ahead of print 2017\/08\/05","journal-title":"Blood"},{"key":"989_CR10","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1182\/blood.2020010263","volume":"139","author":"C Casulo","year":"2022","unstructured":"Casulo C, Dixon JG, Le-Rademacher J, Hoster E, Hochster HS, Hiddemann W, et al. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. Blood. 2022;139:1684\u201393. https:\/\/doi.org\/10.1182\/blood.2020010263. e-pub ahead of print 2021\/10\/07","journal-title":"Blood"},{"key":"989_CR11","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","volume":"127","author":"P Martin","year":"2016","unstructured":"Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016;127:1559\u201363. https:\/\/doi.org\/10.1182\/blood-2015-10-673145. e-pub ahead of print 2016\/01\/15","journal-title":"Blood"},{"key":"989_CR12","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","volume":"130","author":"CW Eskelund","year":"2017","unstructured":"Eskelund CW, Dahl C, Hansen JW, Westman M, Kolstad A, Pedersen LB, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130:1903\u201310. https:\/\/doi.org\/10.1182\/blood-2017-04-779736. e-pub ahead of print 2017\/08\/19","journal-title":"Blood"},{"key":"989_CR13","doi-asserted-by":"publisher","first-page":"1035276","DOI":"10.3389\/fimmu.2022.1035276","volume":"13","author":"J Wei","year":"2022","unstructured":"Wei J, Yang Y, Wang G, Liu M. Current landscape and future directions of bispecific antibodies in cancer immunotherapy. Front Immunol. 2022;13:1035276 https:\/\/doi.org\/10.3389\/fimmu.2022.1035276. e-pub ahead of print 2022\/11\/18","journal-title":"Front Immunol"},{"key":"989_CR14","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn AF, Janmaat ML, Reichert JM, Parren P. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18:585\u2013608. https:\/\/doi.org\/10.1038\/s41573-019-0028-1. e-pub ahead of print 2019\/06\/09","journal-title":"Nat Rev Drug Discov"},{"key":"989_CR15","unstructured":"FDA Approves Genentech\u2019s Columvi, the First and Only Bispecific Antibody With a Fixed-Duration Treatment for People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. In, 2023."},{"key":"989_CR16","doi-asserted-by":"publisher","first-page":"585","DOI":"10.4049\/jimmunol.1900496","volume":"203","author":"A Trabolsi","year":"2019","unstructured":"Trabolsi A, Arumov A, Schatz JH. T Cell-Activating Bispecific Antibodies in Cancer Therapy. J Immunol. 2019;203:585\u201392. https:\/\/doi.org\/10.4049\/jimmunol.1900496. e-pub ahead of print 2019\/07\/25","journal-title":"J Immunol"},{"key":"989_CR17","doi-asserted-by":"publisher","first-page":"e14291","DOI":"10.15252\/emmm.202114291","volume":"13","author":"S Wang","year":"2021","unstructured":"Wang S, Chen K, Lei Q, Ma P, Yuan AQ, Zhao Y, et al. The state of the art of bispecific antibodies for treating human malignancies. EMBO Mol Med. 2021;13:e14291 https:\/\/doi.org\/10.15252\/emmm.202114291. e-pub ahead of print 2021\/08\/26","journal-title":"EMBO Mol Med"},{"key":"989_CR18","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1200\/jco.21.00931","volume":"40","author":"LE Budde","year":"2022","unstructured":"Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon SS, Yoon DH, et al. Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. J Clin Oncol. 2022;40:481\u201391. https:\/\/doi.org\/10.1200\/jco.21.00931. e-pub ahead of print 2021\/12\/17","journal-title":"J Clin Oncol"},{"key":"989_CR19","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1200\/jco.20.03175","volume":"39","author":"M Hutchings","year":"2021","unstructured":"Hutchings M, Morschhauser F, Iacoboni G, Carlo-Stella C, Offner FC, Sureda A, et al. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. J Clin Oncol. 2021;39:1959\u201370. https:\/\/doi.org\/10.1200\/jco.20.03175. e-pub ahead of print 2021\/03\/20","journal-title":"J Clin Oncol"},{"key":"989_CR20","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1200\/jco.22.01725","volume":"41","author":"C Thieblemont","year":"2023","unstructured":"Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, et al. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I\/II Trial. J Clin Oncol. 2023;41:2238\u201347. https:\/\/doi.org\/10.1200\/jco.22.01725. e-pub ahead of print 2022\/12\/23","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"989_CR21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/blood-2020-136659","volume":"136","author":"R Bannerji","year":"2020","unstructured":"Bannerji R, Allan JN, Arnason JE, Brown JR, Advani R, Ansell SM, et al. Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy. Blood. 2020;136(Supplement 1):42\u20133. https:\/\/doi.org\/10.1182\/blood-2020-136659","journal-title":"Blood"},{"issue":"Supplement 1","key":"989_CR22","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1182\/blood-2021-144350","volume":"138","author":"K Patel","year":"2021","unstructured":"Patel K, Michot J-M, Chanan-Khan A, Ghesquieres H, Bouabdallah K, Byrd JC, et al. Safety and Anti-Tumor Activity of Plamotamab (XmAb13676), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Subjects with Relapsed\/Refractory Non-Hodgkin\u2019s Lymphoma. Blood. 2021;138(Supplement 1):2494\u20132494. https:\/\/doi.org\/10.1182\/blood-2021-144350","journal-title":"Blood"},{"issue":"Supplement 1","key":"989_CR23","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1182\/blood-2022-157691","volume":"140","author":"NL Bartlett","year":"2022","unstructured":"Bartlett NL, Sehn LH, Matasar MJ, Schuster SJ, Assouline S, Giri P, et al. Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed\/Refractory Follicular Lymphoma Who Received \u2265 2 Prior Therapies: Updated Results from a Pivotal Phase II Study. Blood. 2022;140(Supplement 1):1467\u201370. https:\/\/doi.org\/10.1182\/blood-2022-157691","journal-title":"Blood"},{"issue":"Supplement 1","key":"989_CR24","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1182\/blood-2022-158024","volume":"140","author":"M Dreyling","year":"2022","unstructured":"Dreyling M, Dickinson M, Martinez Lopez J, Kolstad A, Butler JP, Ghosh M, et al. Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed\/Refractory Follicular Lymphoma (r\/r FL) Treated with Tisagenlecleucel in the Elara Trial. Blood. 2022;140(Supplement 1):1459\u201363. https:\/\/doi.org\/10.1182\/blood-2022-158024","journal-title":"Blood"},{"key":"989_CR25","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/s1470-2045(22)00335-7","volume":"23","author":"LE Budde","year":"2022","unstructured":"Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Giri P, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23:1055\u201365. https:\/\/doi.org\/10.1016\/s1470-2045(22)00335-7. e-pub ahead of print 2022\/07\/09","journal-title":"Lancet Oncol"},{"issue":"Suppl","key":"989_CR26","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1097\/01.HS9.0000847372.57687.d4","volume":"6","author":"M Matasar","year":"2022","unstructured":"Matasar M, Bartlett NL, Sehn LH, Schuster SJ, Assouline S, Giri P, et al. P1126: Mosunetuzumab Is Efficacious and Well Tolerated in Patients Aged < 65 and \u2265 65 Years with Relapsed\/Refractory Follicular Lymphoma and \u2265 2 Prior Therapies: Subgroup Analysis of a Pivotal Phase Ii Study. Hemasphere. 2022;6(Suppl):1016\u20137. https:\/\/doi.org\/10.1097\/01.HS9.0000847372.57687.d4. JuneCollection 2022 Jun","journal-title":"Hemasphere"},{"issue":"Supplement 1","key":"989_CR27","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1182\/blood-2022-157768","volume":"140","author":"AJ Olszewski","year":"2022","unstructured":"Olszewski AJ, Avigdor A, Babu S, Levi I, Eradat H, Abadi U, et al. Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly\/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma. Blood. 2022;140(Supplement 1):1778\u201380. https:\/\/doi.org\/10.1182\/blood-2022-157768","journal-title":"Blood"},{"key":"989_CR28","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.1158\/1078-0432.ccr-18-0455","volume":"24","author":"M Bacac","year":"2018","unstructured":"Bacac M, Colombetti S, Herter S, Sam J, Perro M, Chen S, et al. CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies. Clin Cancer Res : Off J Am Assoc Cancer Res. 2018;24:4785\u201397. https:\/\/doi.org\/10.1158\/1078-0432.ccr-18-0455. e-pub ahead of print 2018\/05\/03","journal-title":"Clin Cancer Res : Off J Am Assoc Cancer Res"},{"key":"989_CR29","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"MJ Dickinson","year":"2022","unstructured":"Dickinson MJ, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G, et al. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N. Engl J Med. 2022;387:2220\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2206913. e-pub ahead of print 2022\/12\/13","journal-title":"N. Engl J Med"},{"key":"989_CR30","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/s0140-6736(21)00889-8","volume":"398","author":"M Hutchings","year":"2021","unstructured":"Hutchings M, Mous R, Clausen MR, Johnson P, Linton KM, Chamuleau MED, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study. Lancet (Lond, Engl). 2021;398:1157\u201369. https:\/\/doi.org\/10.1016\/s0140-6736(21)00889-8. e-pub ahead of print 2021\/09\/12","journal-title":"Lancet (Lond, Engl)"},{"key":"989_CR31","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1093\/annonc\/mdv111","volume":"26","author":"CY Cheah","year":"2015","unstructured":"Cheah CY, Chihara D, Romaguera JE, Fowler NH, Seymour JF, Hagemeister FB, et al. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol : Off J Eur Soc Med Oncol. 2015;26:1175\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdv111. e-pub ahead of print 2015\/02\/26","journal-title":"Ann Oncol : Off J Eur Soc Med Oncol"},{"key":"989_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0209-5","volume":"9","author":"A Kumar","year":"2019","unstructured":"Kumar A, Sha F, Toure A, Dogan A, Ni A, Batlevi CL, et al. Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse. Blood Cancer J. 2019;9:50 https:\/\/doi.org\/10.1038\/s41408-019-0209-5. e-pub ahead of print 2019\/05\/22","journal-title":"Blood Cancer J"},{"key":"989_CR33","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1182\/bloodadvances.2021005954","volume":"6","author":"AE Br\u00f6ske","year":"2022","unstructured":"Br\u00f6ske AE, Korfi K, Belousov A, Wilson S, Ooi CH, Bolen CR, et al. Pharmacodynamics and molecular correlates of response to glofitamab in relapsed\/refractory non-Hodgkin lymphoma. Blood Adv. 2022;6:1025\u201337. https:\/\/doi.org\/10.1182\/bloodadvances.2021005954. e-pub ahead of print 2021\/12\/24","journal-title":"Blood Adv"},{"key":"989_CR34","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1182\/blood-2020-137499","volume":"136","author":"J Brouwer-Visser","year":"2020","unstructured":"Brouwer-Visser J, Fiaschi N, Deering RP, Dhanik A, Cygan KJ, Zhang W, et al. Baseline Biomarkers of T-Cell Function Correlate with Clinical Responses to Odronextamab (REGN1979), and Loss of CD20 Target Antigen Expression Identified As a Mechanism of Treatment Resistance. Blood. 2020;136:10\u201311. https:\/\/doi.org\/10.1182\/blood-2020-137499","journal-title":"Blood"},{"issue":"16_suppl","key":"989_CR35","doi-asserted-by":"publisher","first-page":"7526","DOI":"10.1200\/JCO.2022.40.16_suppl.7526","volume":"40","author":"SJ Schuster","year":"2022","unstructured":"Schuster SJ, Huw L-Y, Bolen CR, Assouline SE, Bartlett NL, Budde LE, et al. Characterization of CD20 expression loss as a mechanism of resistance to mosunetuzumab in patients with relapsed\/refractory B-cell non-Hodgkin lymphomas. J Clin Oncol. 2022;40(16_suppl):7526\u20137526. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.7526","journal-title":"J Clin Oncol"},{"key":"989_CR36","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1182\/blood.2021011994","volume":"141","author":"L Falchi","year":"2023","unstructured":"Falchi L, Vardhana SA, Salles GA. Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities. Blood. 2023;141:467\u201380. https:\/\/doi.org\/10.1182\/blood.2021011994","journal-title":"Blood"},{"key":"989_CR37","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1182\/blood.2022015956","volume":"140","author":"N Philipp","year":"2022","unstructured":"Philipp N, Kazerani M, Nicholls A, Vick B, Wulf J, Straub T, et al. T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals. Blood. 2022;140:1104\u201318. https:\/\/doi.org\/10.1182\/blood.2022015956. e-pub ahead of print 2022\/07\/26","journal-title":"Blood"},{"key":"989_CR38","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1038\/leu.2017.41","volume":"31","author":"J Duell","year":"2017","unstructured":"Duell J, Dittrich M, Bedke T, Mueller T, Eisele F, Rosenwald A, et al. Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL. Leukemia. 2017;31:2181\u201390. https:\/\/doi.org\/10.1038\/leu.2017.41. e-pub ahead of print 2017\/01\/26","journal-title":"Leukemia"},{"issue":"Suppl","key":"989_CR39","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1097\/01.HS9.0000847704.12245.1f","volume":"6","author":"EC Piccione","year":"2022","unstructured":"Piccione EC, Belousov A, Hamidi H, Carlo-Stella C, Dickinson M, Morschhauser F, et al. P1210: Immune Correlates of Response to Glofitamab: Biomarker Findings from a Pivotal Phase Ii Expansion Study in Patients with Relapsed or Refractory (R\/R) Diffuse Large B-Cell Lymphoma (Dlbcl). Hemasphere. 2022;6(Suppl):1096\u20137. https:\/\/doi.org\/10.1097\/01.HS9.0000847704.12245.1f. JuneCollection 2022 Jun","journal-title":"Hemasphere"},{"key":"989_CR40","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1016\/s2352-3026(22)00072-2","volume":"9","author":"R Bannerji","year":"2022","unstructured":"Bannerji R, Arnason JE, Advani RH, Brown JR, Allan JN, Ansell SM, et al. Odronextamab, a human CD20 \u00d7 CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022;9:e327\u2013e339. https:\/\/doi.org\/10.1016\/s2352-3026(22)00072-2. e-pub ahead of print 2022\/04\/04","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"989_CR41","doi-asserted-by":"publisher","first-page":"9443","DOI":"10.1182\/blood-2022-158245","volume":"140","author":"T Phillips","year":"2022","unstructured":"Phillips T, Thieblemont C, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, et al. Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed\/Refractory (R\/R) Large B-Cell Lymphoma (LBCL). Blood. 2022;140(Supplement 1):9443\u20135. https:\/\/doi.org\/10.1182\/blood-2022-158245","journal-title":"Blood"},{"issue":"16_suppl","key":"989_CR42","doi-asserted-by":"publisher","first-page":"7500","DOI":"10.1200\/JCO.2022.40.16_suppl.7500","volume":"40","author":"M Dickinson","year":"2022","unstructured":"Dickinson M, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G, et al. Glofitamab in patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) and \u2265 2 prior therapies: Pivotal phase II expansion results. J Clin Oncol. 2022;40(16_suppl):7500\u20137500. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.7500","journal-title":"J Clin Oncol"},{"key":"989_CR43","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.3390\/cancers14102516","volume":"14","author":"V Rentsch","year":"2022","unstructured":"Rentsch V, Seipel K, Banz Y, Wiedemann G, Porret N, Bacher U, et al. Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy. Cancers (Basel). 2022;14:2516.","journal-title":"Cancers (Basel)"},{"issue":"Supplement 1","key":"989_CR44","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1182\/blood-2022-169219","volume":"140","author":"G Iacoboni","year":"2022","unstructured":"Iacoboni G, Iraola-Truchuelo J, Mussetti A, Fern\u00e1ndez-Caldas P, Navarro Garc\u00e9s V, Martin Lopez AA, et al. Salvage Treatment with Novel Agents Is Preferable to Standard Chemotherapy in Patients with Large B-Cell Lymphoma Progressing after Chimeric Antigen Receptor T-Cell Therapy. Blood. 2022;140(Supplement 1):378\u201380. https:\/\/doi.org\/10.1182\/blood-2022-169219","journal-title":"Blood"},{"key":"989_CR45","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1182\/blood.2022016945","volume":"140","author":"R Di Blasi","year":"2022","unstructured":"Di Blasi R, Le Gouill S, Bachy E, Cartron G, Beauvais D, Le Bras F, et al. Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis. Blood. 2022;140:2584\u201393. https:\/\/doi.org\/10.1182\/blood.2022016945. e-pub ahead of print 2022\/09\/20","journal-title":"Blood"},{"issue":"Supplement 1","key":"989_CR46","doi-asserted-by":"publisher","first-page":"9461","DOI":"10.1182\/blood-2022-157011","volume":"140","author":"M Hutchings","year":"2022","unstructured":"Hutchings M, Carlo-Stella C, Gritti G, Bosch F, Morschhauser F, Townsend W, et al. CD19 4-1BBL (RO7227166) a Novel Costimulatory Bispecific Antibody Can be Safely Combined with the T-Cell-Engaging Bispecific Antibody Glofitamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. Blood. 2022;140(Supplement 1):9461\u20133. https:\/\/doi.org\/10.1182\/blood-2022-157011","journal-title":"Blood"},{"issue":"Supplement 1","key":"989_CR47","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1182\/blood-2022-168904","volume":"140","author":"H Lu","year":"2022","unstructured":"Lu H, Oka A, Coulson M, Polli JR, Aardalen K, Ramones M, et al. PIT565, a First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody for the Treatment of B Cell Malignancies. Blood. 2022;140(Supplement 1):3148\u20133148. https:\/\/doi.org\/10.1182\/blood-2022-168904","journal-title":"Blood"},{"key":"989_CR48","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s43018-019-0004-z","volume":"1","author":"L Wu","year":"2020","unstructured":"Wu L, Seung E, Xu L, Rao E, Lord DM, Wei RR, et al. Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation. Nat cancer. 2020;1:86\u201398. https:\/\/doi.org\/10.1038\/s43018-019-0004-z. e-pub ahead of print 2020\/01\/01","journal-title":"Nat cancer"},{"key":"989_CR49","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1182\/blood.2022016243","volume":"140","author":"L Zhao","year":"2022","unstructured":"Zhao L, Li S, Wei X, Qi X, Liu D, Liu L, et al. A novel CD19\/CD22\/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL. Blood. 2022;140:1790\u2013802. https:\/\/doi.org\/10.1182\/blood.2022016243. e-pub ahead of print 2022\/08\/19","journal-title":"Blood"},{"key":"989_CR50","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1056\/NEJMoa1805104","volume":"379","author":"F Morschhauser","year":"2018","unstructured":"Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, et al. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. N. Engl J Med. 2018;379:934\u201347. https:\/\/doi.org\/10.1056\/NEJMoa1805104. e-pub ahead of print 2018\/09\/06","journal-title":"N. Engl J Med"},{"key":"989_CR51","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1200\/jco.22.00843","volume":"40","author":"F Morschhauser","year":"2022","unstructured":"Morschhauser F, Nastoupil L, Feugier P, Schiano de Colella JM, Tilly H, Palomba ML, et al. Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R(2)) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma. J Clin Oncol. 2022;40:3239\u201345. https:\/\/doi.org\/10.1200\/jco.22.00843. e-pub ahead of print 2022\/08\/11","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"989_CR52","doi-asserted-by":"publisher","first-page":"7524","DOI":"10.1200\/JCO.2022.40.16_suppl.7524","volume":"40","author":"L Falchi","year":"2022","unstructured":"Falchi L, Lepp\u00e4 S, Wahlin BE, Nijland M, Christensen JH, Vos SD, et al. Subcutaneous epcoritamab with rituximab + lenalidomide (R2) in patients (pts) with relapsed or refractory (R\/R) follicular lymphoma (FL): Update from phase 1\/2 trial. J Clin Oncol. 2022;40(16_suppl):7524\u20137524. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.7524","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"989_CR53","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1182\/blood-2021-145694","volume":"138","author":"F Morschhauser","year":"2021","unstructured":"Morschhauser F, Bishton M, Eyre TA, Bachy E, Cartron G, Ysebaert L, et al. Mosunetuzumab in Combination with Lenalidomide Has a Manageable Safety Profile and Encouraging Activity in Patients with Relapsed\/Refractory Follicular Lymphoma: Initial Results from a Phase Ib Study. Blood. 2021;138(Supplement 1):129\u2013129. https:\/\/doi.org\/10.1182\/blood-2021-145694","journal-title":"Blood"},{"issue":"Supplement 1","key":"989_CR54","doi-asserted-by":"publisher","first-page":"9338","DOI":"10.1182\/blood-2022-157584","volume":"140","author":"L Falchi","year":"2022","unstructured":"Falchi L, Morschhauser F, Gribben JG, Huang H, Dinh M, Conlon R, et al. Phase 3 Trial of Subcutaneous Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Vs R2 Among Patients with Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1). Blood. 2022;140(Supplement 1):9338\u20139. https:\/\/doi.org\/10.1182\/blood-2022-157584","journal-title":"Blood"},{"issue":"Supplement 1","key":"989_CR55","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1182\/blood-2022-158232","volume":"140","author":"L Falchi","year":"2022","unstructured":"Falchi L, Leslie LA, Belada D, Kopeckova K, Offner F, Brody J, et al. Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R2) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1\/2 Trial. Blood. 2022;140(Supplement 1):1471\u20133. https:\/\/doi.org\/10.1182\/blood-2022-158232","journal-title":"Blood"},{"issue":"Supplement 1","key":"989_CR56","doi-asserted-by":"publisher","first-page":"3757","DOI":"10.1182\/blood-2022-159594","volume":"140","author":"AJ Olszewski","year":"2022","unstructured":"Olszewski AJ, Budde LE, Chavez J, Ghosh N, Kamdar M, Lossos IS, et al. Mosunetuzumab with Polatuzumab Vedotin Is Effective and Has a Manageable Safety Profile in Patients Aged <65 and \u2265 65 Years with Relapsed\/Refractory Diffuse Large B-Cell Lymphoma (R\/R DLBCL) and \u2265 1 Prior Therapy: Subgroup Analysis of a Phase Ib\/II Study. Blood. 2022;140(Supplement 1):3757\u20139. https:\/\/doi.org\/10.1182\/blood-2022-159594","journal-title":"Blood"},{"issue":"Supplement 1","key":"989_CR57","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1182\/blood-2021-148359","volume":"138","author":"M Hutchings","year":"2021","unstructured":"Hutchings M, Sureda A, Terol MJ, Bosch Albareda F, Corradini P, Larsen TS, et al. Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Phase Ib\/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed\/Refractory (R\/R) Diffuse Large B-Cell Lymphoma (DLBCL). Blood. 2021;138(Supplement 1):525\u2013525. https:\/\/doi.org\/10.1182\/blood-2021-148359","journal-title":"Blood"},{"issue":"Supplement 1","key":"989_CR58","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1182\/blood-2022-158278","volume":"140","author":"P Abrisqueta","year":"2022","unstructured":"Abrisqueta P, Cordoba R, Falchi L, de Vos S, Nijland M, Offner F, et al. Subcutaneous Epcoritamab + R-Dhax\/C in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Eligible for Autologous Stem Cell Transplant: Updated Phase 1\/2 Results. Blood. 2022;140(Supplement 1):1068\u20139. https:\/\/doi.org\/10.1182\/blood-2022-158278","journal-title":"Blood"},{"issue":"Supplement 1","key":"989_CR59","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1182\/blood-2022-157732","volume":"140","author":"MS Topp","year":"2022","unstructured":"Topp MS, Tani M, Dickinson M, Ghosh N, Santoro A, Pinto A, et al. Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study. Blood. 2022;140(Supplement 1):1775\u20137. https:\/\/doi.org\/10.1182\/blood-2022-157732","journal-title":"Blood"},{"issue":"16_suppl","key":"989_CR60","doi-asserted-by":"publisher","first-page":"7523","DOI":"10.1200\/JCO.2022.40.16_suppl.7523","volume":"40","author":"L Falchi","year":"2022","unstructured":"Falchi L, Offner F, Belada D, Brody J, Linton KM, Karimi Y, et al. First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) + R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1\/2 data update. J Clin Oncol. 2022;40(16_suppl):7523\u20137523. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.7523","journal-title":"J Clin Oncol"},{"key":"989_CR61","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1182\/blood-2021-153355","volume":"138","author":"E Budde","year":"2021","unstructured":"Budde E, Gopal AK, Kim WS, Flinn IW, Cheah CYY, Nastoupil L, et al. A Phase 1 Dose Escalation Study of Igm-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies. Blood. 2021;138:132 https:\/\/doi.org\/10.1182\/blood-2021-153355","journal-title":"Blood"},{"issue":"Supplement 1","key":"989_CR62","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1182\/blood-2022-166385","volume":"140","author":"J-Z Hou","year":"2022","unstructured":"Hou J-Z, Jacobs R, Cho S-G, Devata S, Gaballa S, Yoon DH, et al. Interim Results of the Phase 1 Study of Tnb-486, a Novel CD19xCD3 T-Cell Engager, in Patients with Relapsed\/Refractory (R\/R) B-NHL. Blood. 2022;140(Supplement 1):1474\u20135. https:\/\/doi.org\/10.1182\/blood-2022-166385","journal-title":"Blood"},{"key":"989_CR63","doi-asserted-by":"publisher","first-page":"859177","DOI":"10.3389\/fimmu.2022.859177","volume":"13","author":"M Tarannum","year":"2022","unstructured":"Tarannum M, Romee R, Shapiro RM. Innovative Strategies to Improve the Clinical Application of NK Cell-Based Immunotherapy. Front Immunol. 2022;13:859177 https:\/\/doi.org\/10.3389\/fimmu.2022.859177. e-pub ahead of print 2022\/04\/12","journal-title":"Front Immunol"},{"key":"989_CR64","doi-asserted-by":"publisher","first-page":"728","DOI":"10.4161\/mabs.28591","volume":"6","author":"U Reusch","year":"2014","unstructured":"Reusch U, Burkhardt C, Fucek I, Le Gall F, Le Gall M, Hoffmann K, et al. A novel tetravalent bispecific TandAb (CD30\/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells. mAbs. 2014;6:728\u201339. https:\/\/doi.org\/10.4161\/mabs.28591. e-pub ahead of print 2014\/03\/29","journal-title":"mAbs"},{"key":"989_CR65","doi-asserted-by":"publisher","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","volume":"125","author":"A Rothe","year":"2015","unstructured":"Rothe A, Sasse S, Topp MS, Eichenauer DA, Hummel H, Reiners KS, et al. A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2015;125:4024\u201331. https:\/\/doi.org\/10.1182\/blood-2014-12-614636. e-pub ahead of print 2015\/04\/19","journal-title":"Blood"},{"issue":"Supplement 1","key":"989_CR66","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1182\/blood-2022-156125","volume":"140","author":"Y Nieto","year":"2022","unstructured":"Nieto Y, Banerjee PP, Kaur I, Griffin L, Ganesh C, Kerbauy L, et al. Innate Cell Engager AFM13 Combined with Preactivated and Expanded Cord Blood-Derived NK Cells for Patients with Double Refractory CD30+ Lymphoma. Blood. 2022;140(Supplement 1):415\u20136. https:\/\/doi.org\/10.1182\/blood-2022-156125","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-00989-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-00989-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-00989-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T01:02:43Z","timestamp":1706144563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-00989-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["989"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-00989-w","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,25]]},"assertion":[{"value":"2 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}